Search - tctmd.com

Displaying 1 - 9 of 9

Sort: Relevancy | Date

Shelf-stable Product May Sub in for Frozen Plasma in Cardiac Surgery: FARES-II

News Conference News ACC 2025

Shelf-stable Product May Sub in for Frozen Plasma in Cardiac Surgery: FARES-II

March 31, 2025

UK Mini Mitral: No Clear Win for Minimally Invasive MV Repair

News Conference News ACC 2023

UK Mini Mitral: No Clear Win for Minimally Invasive MV Repair

March 13, 2023

How Dapagliflozin Works in HFpEF: Some Clues From CAMEO-DAPA

News Conference News ACC 2023

How Dapagliflozin Works in HFpEF: Some Clues From CAMEO-DAPA

March 09, 2023

METEORIC-HF: Omecamtiv Mecarbil Doesn’t Boost Exercise Capacity in HFrEF

News Conference News ACC 2022

METEORIC-HF: Omecamtiv Mecarbil Doesn’t Boost Exercise Capacity in HFrEF

April 08, 2022

Sodium Nitrite Fails to Improve Survival in Out-of-Hospital Cardiac Arrest

News Conference News ACC 2020

Sodium Nitrite Fails to Improve Survival in Out-of-Hospital Cardiac Arrest

Yael L. Maxwell

April 08, 2020

Urgent/Emergent TAVR: Risky but Rewarding, TVT Registry Data Hint

News Conference News ACC 2018

Urgent/Emergent TAVR: Risky but Rewarding, TVT Registry Data Hint

March 19, 2018

Flu Vaccine Reduces Mortality, Hospitalization in HF Patients: Meta-analysis

News Conference News ACC 2018

Flu Vaccine Reduces Mortality, Hospitalization in HF Patients: Meta-analysis

Michael O'Riordan

March 01, 2018

Cerebral Embolic Protection During Surgical AVR Fails to Show a Benefit

News Conference News ACC 2017

Cerebral Embolic Protection During Surgical AVR Fails to Show a Benefit

March 19, 2017

ACC 2017: CVD Outcomes for Evolocumab, Intermediate-Risk TAVR, Coronary Physiology Tests, and More

News Conference News ACC 2017

ACC 2017: CVD Outcomes for Evolocumab, Intermediate-Risk TAVR, Coronary Physiology Tests, and More

March 10, 2017

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.